Icotinib

also known as Conmana · Icotinib Hydrochloride · Bpi-2009 · BPI-2009H · ectinib

Small molecule targets EGFR via inhibition

Developed for: non-small cell lung carcinoma · metastatic malignant neoplasm in the brain · lung cancer · adenocarcinoma · lung adenocarcinoma · psoriasis · cancer of unknown primary site · malignant pancreatic neoplasm
+16 more
· nasopharyngeal carcinoma · acoustic neuroma · adenosquamous lung carcinoma · breast cancer · bronchial neoplasm · carcinoma of esophagus · esophageal cancer · esophageal squamous cell carcinoma · gastroesophageal junction adenocarcinoma · lung carcinoma · lung large cell carcinoma · lung neoplasm · metastatic malignant neoplasm · neoplastic disease or syndrome · NF2-related schwannomatosis · squamous cell lung carcinoma
Investigated by: Betta Pharmaceuticals Co., Ltd. · Sun Yat-sen University · Tianjin Medical University Cancer Institute and Hospital · Nanfang Hospital, Southern Medical University · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Chinese Academy of Medical Sciences
+48 more
· Guangdong Association of Clinical Trials · Tigermed Consulting Co., Ltd · Zhejiang Cancer Hospital · Zhejiang University · 307 Hospital of PLA · 309th Hospital of Chinese People's Liberation Army · Affiliated Hospital of Jiangnan University · Anhui Medical University · Beijing Haidian Hospital · Beta Pharma, Inc. · Changzhou No.2 People's Hospital · Chinese PLA General Hospital · Daping Hospital and the Research Institute of Surgery of the Third Military Medical University · First People's Hospital of Hangzhou · Fuda Cancer Hospital, Guangzhou · Fujian Cancer Hospital · Fuzhou General Hospital · Guangdong Provincial People's Hospital · Hangzhou Cancer Hospital · Hebei Medical University Fourth Hospital · Henan Cancer Hospital · Henan Provincial People's Hospital · Jiangsu Simcere Pharmaceutical Co., Ltd. · Jiangyin People's Hospital · Li Peng · Liaoning Cancer Hospital & Institute · LuBing · Nanchang University · Nantong University · Peking University Cancer Hospital & Institute · Peking University People's Hospital · People's Hospital of Guangxi Zhuang Autonomous Region · Qilu Hospital of Shandong University · Quintiles, Inc. · Roswell Park Cancer Institute · Second Affiliated Hospital of Nanchang University · Second Affiliated Hospital of Soochow University · Shandong Cancer Hospital and Institute · Shanghai Chest Hospital · Sichuan Cancer Hospital and Research Institute · Taizhou Hospital · The First Affiliated Hospital of Guangzhou Medical University · The First Affiliated Hospital of Soochow University · The First Affiliated Hospital of Xiamen University · The First People's Hospital of Changzhou · Wu Nan · Yuhong Li · Zaiwen Fan

Trials 84 · started per year

today

2009201020112012201320142015201620172018201920202021202220232024202520262027

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 01 trial
Phase 0	NCT07458919	Mar 2026 → Oct 2030 expected	lung cancer	Fuzhou General Hospital	Not yet recruiting	No outcome recorded
Phase 16 trials
Phase 1	NCT02801435	Sep 2016 → Jun 2017	psoriasis	Betta Pharmaceuticals Co., Ltd.	Completed	No outcome recorded
Phase 1	NCT02574091	Nov 2015 → Feb 2017	psoriasis	Betta Pharmaceuticals Co., Ltd.	Completed	No outcome recorded
Phase 1	NCT02278458	Oct 2014 → Jan 2016	malignant pancreatic neoplasm	Betta Pharmaceuticals Co., Ltd.	Unknown	No outcome recorded
Phase 1	NCT02033148	Aug 2014 → Jun 2016	cancer of unknown primary site	Roswell Park Cancer Institute	Withdrawn	No outcome recorded
Phase 1	NCT02066870	Jan 2014 → Sep 2015	non-small cell lung carcinoma	Betta Pharmaceuticals Co., Ltd.	Unknown	No outcome recorded
Phase 1	NCT02024633	Dec 2013 → Dec 2015	malignant pancreatic neoplasm	Betta Pharmaceuticals Co., Ltd.	Unknown	No outcome recorded
Phase 1/22 trials
Phase 1/2	NCT01534585	Feb 2012 → Feb 2013	nasopharyngeal carcinoma	Taizhou Hospital	Completed	No outcome recorded
Phase 1/2	NCT01516983	Dec 2011 → Jun 2013	metastatic malignant neoplasm in the brain, non-small cell lung carcinoma	Betta Pharmaceuticals Co., Ltd.	Completed	No outcome recorded
Phase 246 trials · 4 met primary · 1 missed
Phase 2	NCT06517953	Jul 2024 → Jul 2026 overdue	non-small cell lung carcinoma	Sun Yat-sen University	Recruiting	No outcome recorded
Phase 2	NCT05536505	Sep 2022 → Oct 2025 overdue	—	Guangdong Association of Clinical Trials	Recruiting	No outcome recorded
Phase 2	NCT05514314	Sep 2022 → Sep 2024	non-small cell lung carcinoma	Wu Nan	Unknown	No outcome recorded
Phase 2	NCT05263947	Jan 2022 → Dec 2023	non-small cell lung carcinoma	Tianjin Medical University Cancer Institute and Hospital	Completed	No outcome recorded
Phase 2	NCT05132985	Jan 2022 → Jul 2024 overdue	non-small cell lung carcinoma	Liaoning Cancer Hospital & Institute	Not yet recruiting	No outcome recorded
Phase 2	NCT05104788	Oct 2021 → Mar 2024 overdue	non-small cell lung carcinoma	Peking University Cancer Hospital & Institute	Recruiting	No outcome recorded
Phase 2	NCT05007938	Aug 2021 → Dec 2024 overdue	non-small cell lung carcinoma	Betta Pharmaceuticals Co., Ltd.	Active not recruiting	No outcome recorded
Phase 2	NCT04193007	Dec 2019 → Dec 2021	metastatic malignant neoplasm in the brain, non-small cell lung carcinoma	Second Affiliated Hospital of Nanchang University	Unknown	No outcome recorded
Phase 2	NCT03754530	Dec 2018 → Jun 2020	metastatic malignant neoplasm in the brain, non-small cell lung carcinoma	Betta Pharmaceuticals Co., Ltd.	Unknown	No outcome recorded
Phase 2	NCT03749213	Dec 2018 → Feb 2022	non-small cell lung carcinoma	Betta Pharmaceuticals Co., Ltd.	Unknown	No outcome recorded
Phase 2	NCT03736837	Dec 2018 → Jan 2021	non-small cell lung carcinoma	Tianjin Medical University Cancer Institute and Hospital	Completed	Met primary
Phase 2	NCT03349203	Oct 2018 → Feb 2022	non-small cell lung carcinoma	Betta Pharmaceuticals Co., Ltd.	Unknown	No outcome recorded
Phase 2	NCT03720873	Oct 2018 → Jun 2021	—	Fujian Cancer Hospital	Unknown	No outcome recorded
Phase 2	NCT03396185	May 2018 → Feb 2022	non-small cell lung carcinoma	Betta Pharmaceuticals Co., Ltd.	Unknown	No outcome recorded
Phase 2	NCT03222622	Nov 2017 → Aug 2018	psoriasis	Betta Pharmaceuticals Co., Ltd.	Terminated	No outcome recorded
Phase 2	NCT03346811	Nov 2017 → May 2019	lung cancer	Betta Pharmaceuticals Co., Ltd.	Unknown	No outcome recorded
Phase 2	NCT03153358	Jun → Nov 2017	lung carcinoma	Sichuan Cancer Hospital and Research Institute	Unknown	No outcome recorded
Phase 2	NCT02960607	Nov 2016 → Jan 2018	non-small cell lung carcinoma	Chinese Academy of Medical Sciences	Unknown	No outcome recorded
Phase 2	NCT02961270	Nov 2016 → Dec 2017	non-small cell lung carcinoma	Chinese Academy of Medical Sciences	Unknown	No outcome recorded
Phase 2	NCT02934256	Jul 2016 → Jul 2018	NF2-related schwannomatosis, acoustic neuroma	Li Peng	Completed	No outcome recorded
Phase 2	NCT02820116	May 2016 → Apr 2023	non-small cell lung carcinoma	Beijing Haidian Hospital	Unknown	No outcome recorded
Phase 2	NCT02737774	Apr 2016 → Oct 2019	lung adenocarcinoma	Henan Cancer Hospital	Unknown	No outcome recorded
Phase 2	NCT02726568	Mar 2016 → Dec 2021	metastatic malignant neoplasm in the brain, non-small cell lung carcinoma	Betta Pharmaceuticals Co., Ltd.	Unknown	No outcome recorded
Phase 2	NCT02375022	Mar 2015 → Mar 2016	lung cancer	Zhejiang University	Unknown	No outcome recorded
Phase 2	NCT02009605	Mar 2015 → Jan 2016	squamous cell lung carcinoma	Zhejiang University	Unknown	No outcome recorded
Phase 2	NCT03544814	Jan 2015 → Jun 2017	lung adenocarcinoma	Shanghai Chest Hospital	Completed	No outcome recorded
Phase 2	NCT02375581	Jan 2015 → Dec 2017	esophageal cancer	First People's Hospital of Hangzhou	Unknown	Met primary
Phase 2	NCT02362230	Jan 2015 → Dec 2020	breast cancer	Sun Yat-sen University	Terminated	No outcome recorded Stop: Enrollment
Phase 2	NCT02264210	Jan 2015 → Dec 2020	adenosquamous lung carcinoma, bronchial neoplasm, lung adenocarcinoma, lung large cell carcinoma	Sun Yat-sen University	Completed	Met primary
Phase 2	NCT02407366	Dec 2014 → Dec 2016	non-small cell lung carcinoma	People's Hospital of Guangxi Zhuang Autonomous Region	Unknown	No outcome recorded
Phase 2	NCT02328261	Nov 2014 → Oct 2016	nasopharyngeal carcinoma	Betta Pharmaceuticals Co., Ltd.	Unknown	No outcome recorded
Phase 2	NCT02215356	Aug 2014 → Aug 2018	non-small cell lung carcinoma	Betta Pharmaceuticals Co., Ltd.	Unknown	No outcome recorded
Phase 2	NCT02272127	Jul 2014 → Jul 2017	non-small cell lung carcinoma	Nanfang Hospital, Southern Medical University	Unknown	No outcome recorded
Phase 2	NCT02191059	Jul 2014 → Jul 2015	non-small cell lung carcinoma	Shandong Cancer Hospital and Institute	Unknown	No outcome recorded
Phase 2	NCT02062515	Feb 2014 → Feb 2016	non-small cell lung carcinoma	Betta Pharmaceuticals Co., Ltd.	Unknown	No outcome recorded
Phase 2	NCT01963195	Feb 2014 → Dec 2018	non-small cell lung carcinoma	Anhui Medical University	Unknown	No outcome recorded
Phase 2	NCT02044328	Jan 2014 → Jan 2018	non-small cell lung carcinoma	Betta Pharmaceuticals Co., Ltd.	Completed	No outcome recorded
Phase 2	NCT01973725	Oct 2013 → Sep 2018	esophageal squamous cell carcinoma	Yuhong Li	Completed	No outcome recorded
Phase 2	NCT01929200	Aug 2013 → Dec 2015	non-small cell lung carcinoma	Betta Pharmaceuticals Co., Ltd.	Unknown	Met primary
Phase 2	NCT01855854	May 2013 → Aug 2015	carcinoma of esophagus, gastroesophageal junction adenocarcinoma	Betta Pharmaceuticals Co., Ltd.	Completed	No outcome recorded
Phase 2	NCT01843647	Apr 2013 → Dec 2016	non-small cell lung carcinoma	Betta Pharmaceuticals Co., Ltd.	Unknown	No outcome recorded
Phase 2	NCT01707329	Sep 2012 → Jul 2016	non-small cell lung carcinoma	Betta Pharmaceuticals Co., Ltd.	Unknown	No outcome recorded
Phase 2	NCT01688713	Aug 2012 → Feb 2015	metastatic malignant neoplasm in the brain, non-small cell lung carcinoma	Zhejiang Cancer Hospital	Unknown	No outcome recorded
Phase 2	NCT01514877	Jan 2012 → Jul 2014	lung cancer, metastatic malignant neoplasm	Zhejiang Cancer Hospital	Completed	No outcome recorded
Phase 2	NCT02738983	Jan 2012 → Dec 2016	non-small cell lung carcinoma	Hangzhou Cancer Hospital	Unknown	No outcome recorded
Phase 2	NCT02430974	Jan 2011 → Jan 2016	non-small cell lung carcinoma	Nanfang Hospital, Southern Medical University	Unknown	Missed primary

Phase 314 trials · 4 met primary
Phase 3	NCT06955325	May 2025 → Dec 2030 expected	non-small cell lung carcinoma	The First Affiliated Hospital of Guangzhou Medical University	Not yet recruiting	No outcome recorded
Phase 3	NCT04797806	Mar 2021 → Apr 2022	non-small cell lung carcinoma	Tianjin Medical University Cancer Institute and Hospital	Unknown	No outcome recorded
Phase 3	NCT03992885	Jul 2019 → Jul 2020	non-small cell lung carcinoma	Tianjin Medical University Cancer Institute and Hospital	Unknown	No outcome recorded
Phase 3	NCT04058704	Jul 2018 → Dec 2022	metastatic malignant neoplasm in the brain, non-small cell lung carcinoma	Betta Pharmaceuticals Co., Ltd.	Unknown	No outcome recorded
Phase 3	NCT03008109	Feb → Nov 2017	cancer of unknown primary site, non-small cell lung carcinoma	Zaiwen Fan	Unknown	No outcome recorded
Phase 3	NCT02883543	Jun 2016 → Jun 2018	non-small cell lung carcinoma	Daping Hospital and the Research Institute of Surgery of the Third Military Medical University	Unknown	No outcome recorded
Phase 3	NCT02714010	Aug 2015 → Dec 2021	non-small cell lung carcinoma	Sun Yat-sen University	Unknown	No outcome recorded
Phase 3	NCT02448797	Jun 2015 → Jun 2022	non-small cell lung carcinoma	Betta Pharmaceuticals Co., Ltd.	Unknown	Met primary
Phase 3	NCT02125240	Sep 2014 → Dec 2018	adenocarcinoma, non-small cell lung carcinoma	Betta Pharmaceuticals Co., Ltd.	Unknown	No outcome recorded
Phase 3	NCT01996098	Jan 2014 → Dec 2021	lung cancer	Sun Yat-sen University	Terminated	No outcome recorded
Phase 3	NCT01719536	Dec 2012 → Sep 2016	non-small cell lung carcinoma	Betta Pharmaceuticals Co., Ltd.	Completed	Met primary
Phase 3	NCT01724801	Oct 2012 → Jun 2015	metastatic malignant neoplasm in the brain, non-small cell lung carcinoma	Guangdong Association of Clinical Trials	Completed	Met primary
Phase 3	NCT02486354	Mar 2010 → Oct 2011	non-small cell lung carcinoma	Betta Pharmaceuticals Co., Ltd.	Completed	No outcome recorded
Phase 3	NCT01040780	Feb 2009 → Mar 2010	non-small cell lung carcinoma	Betta Pharmaceuticals Co., Ltd.	Completed	Met primary

Phase 411 trials · 1 met primary
Phase 4	NCT02744664	Apr 2016 → Aug 2017	lung neoplasm	Fuda Cancer Hospital, Guangzhou	Completed	No outcome recorded
Phase 4	NCT02778893	Mar 2016 → Mar 2017	non-small cell lung carcinoma	Henan Provincial People's Hospital	Unknown	No outcome recorded
Phase 4	NCT02404675	Apr 2015 → Dec 2017	non-small cell lung carcinoma	Betta Pharmaceuticals Co., Ltd.	Unknown	No outcome recorded
Phase 4	NCT02283424	Oct 2014 → Oct 2017	neoplastic disease or syndrome	Chinese PLA General Hospital	Unknown	No outcome recorded
Phase 4	NCT02194556	Jul 2014 → Jul 2017	adenocarcinoma, non-small cell lung carcinoma	Betta Pharmaceuticals Co., Ltd.	Unknown	No outcome recorded
Phase 4	NCT02031601	Jan 2014 → Dec 2016	non-small cell lung carcinoma	Qilu Hospital of Shandong University	Unknown	Met primary
Phase 4	NCT01926171	Jun 2013 → Sep 2016	non-small cell lung carcinoma	Betta Pharmaceuticals Co., Ltd.	Unknown	No outcome recorded
Phase 4	NCT01720901	Feb 2013 → Dec 2015	non-small cell lung carcinoma	Betta Pharmaceuticals Co., Ltd.	Suspended	No outcome recorded Stop: Enrollment
Phase 4	NCT01665417	Aug 2012 → Jul 2017	adenocarcinoma, non-small cell lung carcinoma	Betta Pharmaceuticals Co., Ltd.	Unknown	No outcome recorded
Phase 4	NCT01646450	Jul 2012 → Dec 2015	non-small cell lung carcinoma	Betta Pharmaceuticals Co., Ltd.	Unknown	No outcome recorded
Phase 4	NCT01465243	Sep 2011 → Oct 2013	non-small cell lung carcinoma	Betta Pharmaceuticals Co., Ltd.	Completed	No outcome recorded

Phase not applicable4 trials
—	NCT03983811	Jul 2019 → Oct 2021	non-small cell lung carcinoma	Nanfang Hospital, Southern Medical University	Unknown	No outcome recorded
—	NCT03766490	Mar → Dec 2019	non-small cell lung carcinoma	The First Affiliated Hospital of Soochow University	Unknown	No outcome recorded
—	NCT03634059	Aug 2018 → Aug 2019	non-small cell lung carcinoma	Hebei Medical University Fourth Hospital	Unknown	No outcome recorded
—	NCT03258671	Oct 2017 → Dec 2020	non-small cell lung carcinoma	LuBing	Unknown	No outcome recorded
Comparator or background therapy16 trials
Phase 2	NCT03402464 Background	Jan 2018 → Jun 2019	lung adenocarcinoma	Peking University Cancer Hospital & Institute	Unknown	No outcome recorded
Phase 2	NCT03123484 Background	Apr 2017 → Apr 2019	non-small cell lung carcinoma	China Medical University, China	Unknown	No outcome recorded
Phase 2	NCT03595644 Background	Feb 2017 → Jun 2019	non-small cell lung carcinoma	Tongji Hospital	Completed	No outcome recorded
Phase 2	NCT02788058 Background	May 2016 → May 2021	lung adenocarcinoma	First People's Hospital of Hangzhou	Unknown	No outcome recorded
Phase 2	NCT02787447 Background	May 2016 → Dec 2017	lung adenocarcinoma	First People's Hospital of Hangzhou	Unknown	No outcome recorded
Phase 2	NCT03151161 Comparator	Dec 2015 → Dec 2018	lung carcinoma	Sun Yat-sen University	Unknown	No outcome recorded
Phase 2	NCT02027090 Comparator	Jan 2014 → Jun 2016	non-small cell lung carcinoma	Betta Pharmaceuticals Co., Ltd.	Unknown	No outcome recorded
Phase 2	NCT01744925 Comparator	Oct 2012 → Nov 2017	non-small cell lung carcinoma	Tianjin Medical University Cancer Institute and Hospital	Unknown	No outcome recorded
Phase 2	NCT01690390 Comparator	Sep 2012 → Dec 2015	non-small cell lung carcinoma	Betta Pharmaceuticals Co., Ltd.	Unknown	No outcome recorded
Phase 2/3	NCT04206072 Comparator	Dec 2019 → Jul 2022	non-small cell lung carcinoma	Betta Pharmaceuticals Co., Ltd.	Completed	Met primary
Phase 3	NCT06041776 Comparator	Mar 2023 → Apr 2028 expected	non-small cell lung carcinoma	Betta Pharmaceuticals Co., Ltd.	Recruiting	No outcome recorded
Phase 3	NCT02882984 Background	Mar 2015 → Mar 2020	—	Sichuan Provincial People's Hospital	Unknown	No outcome recorded
Phase 3	NCT02889692 Background	Mar 2013 → Dec 2016	cancer	Shanghai University of Traditional Chinese Medicine	Completed	No outcome recorded
Phase 4	NCT04401059 Comparator	Nov 2020 → Sep 2025	adenocarcinoma, non-small cell lung carcinoma	Tian Xie	Unknown	No outcome recorded
Phase 4	NCT02103257 Comparator	Mar 2014 → Mar 2016	adenocarcinoma, non-small cell lung carcinoma	Betta Pharmaceuticals Co., Ltd.	Unknown	No outcome recorded
—	NCT04007835 Background	Jul 2019 → Jul 2021	non-small cell lung carcinoma	Guangdong Association of Clinical Trials	Unknown	No outcome recorded

News releases announcing trial results or a regulatory action · 3

Date	Issuer	Release
2026-03-23	Betta Pharmaceuticals Co., Ltd.	Results 埃克替尼联合三代EGFR-TKI一线治疗EGFR突变伴脑转移NSCLC患者研究在《Neuro-Oncology》发表 bettapharma.com ↗ 本项临床试验结果表明，阿美替尼联合埃克替尼在携带EGFR突变且基线存在可测量脑转移灶的NSCLC中显示出令人鼓舞的疗效和可耐受的安全性。
2021-06-04	Betta Pharmaceuticals Co., Ltd.	Results 贝达药业埃克替尼和伏罗尼布临床研究成果亮相ASCO年会 bettapharma.com ↗ 研究显示，2年埃克替尼靶向治疗对比1年，显著提高了患者的DFS及OS，同时未见毒性的增加。
2012-06-07	Betta Pharmaceuticals Co., Ltd.	Results 凯美纳再次在ASCO上引起国际肿瘤界的关注 bettapharma.com ↗ 与PFS结果一样，不管是EGFR突变阳性或者突变阴性的肺癌患者中，凯美纳在最终的OS方面与易瑞沙相当，凯美纳vs易瑞沙分别为20.9月vs 20.2月和7.8月vs 6.9月。

All press releases naming this drug 3 releases

Date	Issuer	Release
2026-03-23	Betta Pharmaceuticals Co., Ltd.	埃克替尼联合三代EGFR-TKI一线治疗EGFR突变伴脑转移NSCLC患者研究在《Neuro-Oncology》发表 bettapharma.com ↗
2021-06-04	Betta Pharmaceuticals Co., Ltd.	贝达药业埃克替尼和伏罗尼布临床研究成果亮相ASCO年会 bettapharma.com ↗
2012-06-07	Betta Pharmaceuticals Co., Ltd.	凯美纳再次在ASCO上引起国际肿瘤界的关注 bettapharma.com ↗

Evidence & citations 10 cited values

Every value below carries the sentence it was read from. 102 sources stand behind the page.

Field	Value	Cited text
Known as	Icotinib	“Gefitinib(Iressa,YiRuiKe), Erlotinib(Tarceva), Icotinib(Kaimeina), Osimertinib(Tagrisso), Almonertinib, Furmonertinib, etc.” NCT04401059 ↗ 97 “Standard EGFR-TKI(Gefitinib, erlotinib or icotinib) Gefitinib: 250mg po Qd Erlotinib: 150mg po Qd Icotinib: 125mg po tid” NCT03595644 ↗ “Icotinib is administered 125 mg three times per day, until disease progression or untolerated toxicity.” NCT04007835 ↗ “Icotinib is a new first-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors.” PMID 26148750 ↗ Jul 2015 “apatinib 500mg qd po plus Erlotinib 150mg qd po / apatinib 500mg qd po plus Icotinib 125mg tid po” NCT03634059 ↗ “Gefitinib 250mg po qd or Erlotinib 150mg po qd or Icotinib 125mg po tid” NCT02787447 ↗ “Gefitinib 250mg po qd or Erlotinib 150mg po qd or Icotinib 125mg po tid” NCT02788058 ↗ “Gefitinib 250mg po qd or Tarceva 150mg po qd or Icotinib 125mg po tid” NCT02714010 ↗ “The MRD positive group would receive icotinib as adjuvant treatment.” NCT05536505 ↗ “Icotinib: 125 mg is administered orally three times per day.” NCT01707329 ↗ “Icotinib: 125mg, oral administration, three times per day.” NCT01665417 ↗ Show 87 more sources
Known as	Bpi-2009	ChEMBL registry synonym — accepted as the source's own label CHEMBL2087361 ↗
Known as	BPI-2009H	“Icotinib (BPI-2009H), a novel EGFR tyrosine kinase inhibitor, displays potent efficacy in preclinical studies.” PMID 22112293 ↗ Nov 2011
Known as	Conmana	“The primary purposes of this study are to assess the safety and efficacy of using high doses of the drug Icotinib (Conmana) as a way to treat patients with non-small cell lung...” NCT01690390 ↗ 3 “Erlotinib (trade name: Tarceva®) (150mg oral daily) or Icotinib (trade name: Conmana®) (125mg oral three times a day).” NCT02738983 ↗ “high dose of Icotinib (Conmana)” NCT01720901 ↗ NCT02778893 ↗
Known as	ectinib	“Intervention: Drug: Icotinib Ectinib 125mg/ tablet, one tablet at a time, three times a day, take orally” NCT03992885 ↗
Known as	Icotinib Hydrochloride	“Icotinib Hydrochloride is an oral, small-molecule epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, which has been approved for treating advanced non-small...” NCT03222622 ↗ 3 “To determine the pharmacokinetic (PK) profiles of icotinib (icotinib hydrochloride) in patients with advanced cancers.” NCT02033148 ↗ “Icotinib Hydrochloride is a small-molecule epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor” NCT02574091 ↗ NCT02801435 ↗
Action	Inhibit	“Icotinib, one of the leading compounds selected from our compound library, was found to be a potent and specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI)” PMID 22112293 ↗ Nov 2011
Modality	Small molecule	“Icotinib hydrochloride is a novel oral EGFR TKIs” NCT01534585 ↗
Route	Oral	“Icotinib was administered at 125 mg orally 3 times/day until tumor progression or unacceptable toxicity” PMID 26148750 ↗ Jul 2015
Target	EGFR	“Icotinib, one of the leading compounds selected from our compound library, was found to be a potent and specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI)” PMID 22112293 ↗ Nov 2011